Lyell Immunopharma Announced Initial Clinical And Translational Data From Its Phase 1 Trial Of LYL797, Its First-generation Reprogrammed ROR1 CAR T‑Cell Product Candidate For Blood Cancers
$LYEL
Biotechnology: Pharmaceutical Preparations
Health Care
- Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)
- First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumors
- No significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; dose escalation continues in separate cohorts
- Expanding development into new tumor types including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer, multiple myeloma and chronic lymphocytic leukemia
- IND submission completed for LYL119, Lyell's next generation ROR1-targeted CAR T cell product candidate